2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2109 Rapid tumor depletion and normalization of myeloid and lymphoid immune landscapes underlie the potent activity of the epcoritamab plus venetoclax combination in relapsed/ refractory CLL after targeted therapies

Gregory P. Takacs, PhD, Tessa Annelotte Groeneweg2, Durga Dandamudi3, Andrew J Steele, PhD4, Isil Altintas, PhD5, Julie Dubois, MD, PhD6, Mark-David Levin, MD, PhD7, Michael Hallek Jr, MD8, Barbara Eichhorst, MD9, Kirsten Fischer, MD10, Carsten Utoft Niemann, MD, PhD11, Erik D. van Werkhoven, PhD12, Sabina Kersting13, Edith Szafer Glusman, PhD14, PK Epling-Burnette, PhD, PharmD15, Fleur Peters16, Arnon Philip Kater, MD, PhD17
1 Abbvie, Chicago, Illinois, United States
2 Amsterdam University Medical Centers, Amsterdam, NH, Netherlands
3 Abbvie, Chicago, Illinois, United States
4 Genmab, Utrecht, Netherlands
5 Genmab, Utrecht, Netherlands
6 Amsterdam University Medical Centers, Amsterdam, NH, Netherlands, Genentech, South San Francisco, California, United States, Hoffmann-La Roche, Basel, Switzerland
7 Albert Schweitzer Hospital, Dordrecht, Netherlands, Dordrecht, ZH, Netherlands
8 University Hospital Cologne, Cologne, Germany, Cologne, Germany
9 University Hospital Cologne, Cologne, Germany, Cologne, Germany
10 University Hospital Cologne, Cologne, Germany, Cologne, Germany
11 Rigshospitalet, Copenhagen, Copenhagen, Denmark
12 Erasmus MC and HOVON, Rotterdam, Netherlands
13 Haga Ziekenhuis, Den Haag, ZH, Netherlands
14 Abbvie, Chicago, Illinois, United States
15 Abbvie, Chicago, Illinois, United States
16 Amsterdam University Medical Centers, Amsterdam, NH, Netherlands
17 Amsterdam University Medical Centers, Amsterdam, NH, Netherlands

INTRODUCTION: Relapsed/refractory (R/R) CLL following targeted therapies remains an unmet medical need. While CAR T-cell therapy has limited efficacy in CLL due to profound T-cell dysfunction, the CD3xCD20 bispecific epcoritamab (epcor) has shown promising monotherapy activity which may benefit from improved T-cell function.  The HOVON165/AETHER randomized phase 1/2 trial (NCT05791409) evaluates epcor plus venetoclax (ven), with a ven lead-in designed to rapidly debulk and improve T-cell function. Here we present updated efficacy and treatment-associated immune changes.

METHODS: Following ven ramp-up, R/R CLL patients received 26 cycles of ven with 6 (arm A) or 12 (arm B) cycles of epcor. MRD was assessed every 3 months by central flow cytometry according to ERIC standards. This interim analysis includes the first protocol-defined IWCLL response assessment at C9. Paired PBMCs were analyzed at baseline (BL), after ven ramp-up (C1D1), and after 5 combination cycles (C6D1) (n=11). Age-matched healthy donor (HD) PBMCs (n=8) served as controls.  Cell dynamics were assessed by spectral flow cytometry (CytoPrint) with UMAP. T-cell subsets were defined by lineage, activation, senescence, checkpoint, transcription factor expression, proliferation, and BCL-2 family proteins. Serum proteins were analyzed by proximity extension assay (Olink Reveal; n=16).

RESULTS: At this interim analysis, 46 patients were enrolled; 74% had prior targeted therapy (BTK-i exposed 55%, ven exposed 68% (>24 months earlier), double-exposed 36%). High-risk features were common: IGHV-unmut 70%, TP53 aberrant 42%, bulky disease 37%, genomic complexity >2<5: 14%, >5: 31%. Following the phase 1 protocol amendment with a third epcor priming dose and mandatory dexamethasone prophylaxis, CRS was predominantly grade 1 (36%), with grade 2 and ≥3 CRS in 17% and 3%, respectively; 56% experienced no CRS. No ICANS or clinical TLS were observed. Grade ≥3 infections (mainly respiratory) occurred in 22%. MRD showed rapid and sustained molecular responses, with at least uMRD4 in 80% of evaluable patients at C4 and C6. At first response (C9) ORR was 100%, including CR/CRi in 39% and complete nodal responses in 66%. At this timepoint 80% achieved uMRD in blood and 85% in bone marrow.

CLL cells were reduced during ven ramp-up (21-fold decrease from BL to C1D1; p<0.0001) but remained detectable, and were further depleted following epcor addition (1,680-fold decrease from C1D1 to C6D1, p<0.0001). Although T-cell counts trended lower during ven ramp-up, the effector-to-target ratio progressively increased with treatment (BL=0.03, C1D1=0.22, C6D1=32.8, p<0.0001).  At C6D1, residual CLL cells expressed high BCL-2 without increases in MCL-1 or BCL-XL. T cells from patients showed skewed differentiation, altered TF representation, and an expanded Tregs compartment. CD4 T-cell compartment, including Tregs, remained stable throughout treatment, except for GZMB+CD4 T-cells, which increased by C6D1 (p<0.001). Ven ramp-up increased the proportion of progenitor/stem-like memory CD8 T-cell populations with a trend of reduced TIM3 and LAG3 expression. The proportion of GZMB+ effector-memory CD8 T-cells increased progressively to C6D1 (p<0.0001). A shift from CLL-dominant to a T-cell-supportive state was reflected by decreased circulating CLL/B-cell-associated proteins and increased IL-7, DNAM-1, LAT, and ITPR1. Despite increased T-cell activation, reflected by increased soluble CD40L (p<0.001), T-cell exhaustion did not increase and soluble PD-1 decreased.

In addition, the proportion of monocytes, dendritic cells, and NK cells increased during treatment. Consistently, proteomics showed increased levels of myeloid activation markers (CLEC6A and CD300e), chemotaxis-associated CCL26, and tissue-remodeling proteins VEGF-A, epiregulin, and CCN1.

CONCLUSION: Ven ramp-up followed by epcor combination therapy was well tolerated and induced rapid deep molecular responses in this high-risk R/R CLL population. Treatment shifted the CLL-dominant immune landscape toward an enriched myeloid and lymphoid environment, increasing the T-cell-to-tumor-cell ratio without evidence of T-cell exhaustion or Treg expansion. The profound tumor depletion following epcor addition supports enhanced cytotoxicity of the combination. Persistent BCL-2 expression in residual tumor cells suggests continued susceptibility to ven, supporting completion of the planned 26-cycle regimen to maximize residual disease elimination.

Gregory P. Takacs, PhD: Abbvie - Current Employment